{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:32:30Z","timestamp":1789651950355,"version":"4.0.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003665","name":"National IT Industry Promotion Agency","doi-asserted-by":"publisher","award":["S0252-21-1001"],"award-info":[{"award-number":["S0252-21-1001"]}],"id":[{"id":"10.13039\/501100003665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jhepr.2024.101089","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T15:56:46Z","timestamp":1712591806000},"page":"101089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-8795","authenticated-orcid":false,"given":"Hyunjae","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Mook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeayeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Haeng","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-2080","authenticated-orcid":false,"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101089_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2024.101089_bib5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101089_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2024.101089_bib10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib12","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","article-title":"Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.cgh.2021.09.001","article-title":"Impact of HBeAg on hepatocellular carcinoma risk during oral antiviral treatment in patients with chronic hepatitis B","volume":"20","author":"Jang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib21","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101089_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/07853890310021580","article-title":"Seropositivity of hepatitis B e antigen and hepatocellular carcinoma","volume":"36","author":"You","year":"2004","journal-title":"Ann Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B","volume":"115","author":"Choi","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101089_bib25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00535-020-01700-z","article-title":"Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients","volume":"55","author":"Liang","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101089_bib26","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.31440","article-title":"Risk scores for hepatocellular carcinoma in chronic hepatitis B: a promise for precision medicine","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","article-title":"PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B","volume":"80","author":"Chun","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib28","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10620-010-1179-4","article-title":"Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection","volume":"55","author":"Liaw","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2024.101089_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169444","article-title":"HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis","volume":"12","author":"Xing","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2024.101089_bib30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"van Nunen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101089_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib32","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","article-title":"Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity","volume":"74","author":"Suslov","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib33","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jvh.13547","article-title":"Hepatitis B virus genome diversity in adolescents: tenofovir disoproxil fumarate treatment effect and HBeAg serocon version","volume":"28","author":"Combet","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2024.101089_bib34","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1128\/jvi.70.9.5845-5851.1996","article-title":"Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication","volume":"70","author":"Buckwold","year":"1996","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2024.101089_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/emph\/eot023","article-title":"Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection","volume":"2014","author":"Warner","year":"2014","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.jhepr.2024.101089_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrgastro.2009.107","article-title":"Hepatitis B virus variants","volume":"6","author":"Chotiyaputta","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3350\/cmh.2022.0322","article-title":"Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase","volume":"29","author":"Yoo","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3350\/cmh.2022.0084","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2022.0448","article-title":"The role of different viral biomarkers on the management of chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101089_bib41","first-page":"649","article-title":"Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B","volume":"73","author":"Choi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101089_bib42","doi-asserted-by":"crossref","first-page":"S757","DOI":"10.1093\/infdis\/jix461","article-title":"Viral factors affecting the clinical outcomes of chronic hepatitis B","volume":"216","author":"Yang","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2024.101089_bib43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature","volume":"37","author":"Mommeja-Marin","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101089_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/EDE.0b013e3182109296","article-title":"Compound treatments and transportability of causal inference","volume":"22","author":"Hern\u00e1n","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.jhepr.2024.101089_bib45","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jhepr.2024.101089_bib47","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101089_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000096313","article-title":"Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea","volume":"50","author":"Kim","year":"2007","journal-title":"Intervirology"},{"key":"10.1016\/j.jhepr.2024.101089_bib49","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101089_bib50","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/gast.2002.33588","article-title":"Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C","volume":"122","author":"Chu","year":"2002","journal-title":"Gastroenterology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924000934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924000934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T14:41:21Z","timestamp":1720017681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924000934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2589555924000934"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101089","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101089"}}